Chimeric Therapeutics

Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy | Coverage by ASCO Publications. Read more: https://lnkd.in/g2R3pyfX #CHM #Chimeric #Biotech #ASCO #Cancer #ColorectalCancer

Our CEO, Dr. Rebecca McQualter, shared an update on Patient 2 in our CHM CDH17 Phase 1/2 trial. At 60 days, the patient who had a rapidly progressing neuroendocrine tumour has achieved stable disease, with no new tumour growth or changes in size. This signals early activity and persistence of CHM CDH17 CAR-T cells beyond initial treatment.   These results are an encouraging step in our work to develop a new treatment for gastrointestinal cancers and neuroendocrine tumours.   Watch the update in our webinar here: https://lnkd.in/gVu2W8Ds   #ChimericTherapeutics #CHM #CHMCDH17 #CAR_T #CancerResearch #Oncology #Biotech #ASX #ASXNews

Chimeric was featured in this week’s episode of Tony’s Takeaway, where Tony Locantro highlights four stocks trading under a cent with potential for significant upside. Watch the full episode here: https://lnkd.in/gtdPyrvn #ChimericTherapeutics #CHM #CART #CancerResearch #TonyTakeaway #ASX #Biotech Stockhead

Colorectal cancer remains the third most common cancer and the second leading cause of cancer deaths worldwide. At Chimeric Therapeutics, we're advancing CHM CDH17, a third-generation CAR-T therapy designed to target gastrointestinal cancers, including colorectal cancer. Our ongoing Phase 1/2 clinical trial is assessing its potential in improving patient outcomes. https://lnkd.in/eRqCQ8yB #ColorectalCancerAwareness #ColorectalCancer #CancerResearch #CDH17 #ChimericTherapeutics #CHM

🗞️Chimeric announces US patent allowed for CHM CDH17 technology | Media coverage by Biotech Dispatch. https://lnkd.in/gussbCsn

We've received confirmation from the US Patent and Trademark Office (USPTO) that a patent will be issued for our CHM CDH17 CAR-T technology. This patent protects our third-generation CAR-T therapy targeting gastrointestinal cancers until at least 2039. CHM CDH17 is currently in a Phase 1/2 clinical trial at leading US cancer centres, including the Sarah Cannon Research Institute, the University of Pennsylvania, and UChicago Medicine. Preclinical studies published in Nature Cancer have shown its ability to eliminate tumours while sparing healthy tissue. This patent strengthens our intellectual property position as we continue advancing CHM CDH17 through clinical development. Read more: https://lnkd.in/eUrZTk8w #ChimericTherapeutics #CHM #CDH17 #CART #CancerResearch #GastrointestinalCancer #Oncology #ASX #ASXNews #Biotech

In case you missed it – CEO Dr. Rebecca McQualter’s presentation at the NWR Communications Healthcare Conference is now available to watch. Rebecca shared updates on our CHM CDH17 Phase 1/2 trial, recent funding developments, and what’s ahead for Chimeric. 🎥 Watch the full replay here: https://lnkd.in/gqFHW8eE #ChimericTherapeutics #CHM #CDH17 #CART #Biotech #ASX #Healthcare

REMINDER | CEO Dr. Rebecca McQualter will present tomorrow at 12:20pm AEDT (19 March 2025) as part of the NWR Communications Healthcare Conference. 📌 Register to attend: https://lnkd.in/gRE9hUuy A replay will be available shortly after the session via the same link, as well as on our website and social channels. Questions can be submitted live or in advance via matt@nwrcommunications.com.au. More info: https://lnkd.in/gjepqwZP #ChimericTherapeutics #CDH17 #Biotech #InvestorUpdate #CancerResearch #CHM #Webinar #Conference

We are undertaking a $3.2 million Entitlement Offer to support the continued development of our CHM CDH17 CAR-T Phase 1/2 trial and CHM CORE-NK platform. Eligible shareholders can participate at $0.005 per share on a 2-for-5 basis, with 1 new option per new share (exercise price $0.008, expiring Dec 2025). A top-up facility is available for shareholders who take up their full entitlement. CEO Dr Rebecca McQualter said, “I would like to thank our shareholders for their ongoing support to continue our innovative work to bring cell therapy to patients in need.” More details here: https://lnkd.in/g-8iW7cb A link to the Prospectus can be found here: https://lnkd.in/gWrPYmd8 #ChimericTherapeutics #CHM #CDH17 #CART #Biotech #CancerResearch #ASX

Our Chief Medical Officer, Dr. Jason Litten, is at the 2025 SITC Spring Scientific: Cellular Therapy for Solid Tumours in San Diego, California, connecting with leaders in the field to discuss the latest advancements in cell therapy. With CHM CDH17, we're developing a third-generation CAR T-cell therapy designed to tackle some of the toughest solid tumours, including gastrointestinal cancers, neuroendocrine tumours, and colorectal cancer. Events like SITC are crucial for driving innovation and progress in cell therapy, bringing new hope to patients in need. #ChimericTherapeutics #CDH17 #CAR_T #SITC #CellTherapy #Oncology